ABC1212, Andrew Caravello, DO, is really putting out an amazing set of posts. His idea of precision medicine targets as one of the possibilities in the Franchise offering, makes me think of how revolutionary this can be.
Current process:
- surgery lysate to load tumor antigens onto DCs
- highly personalized but requires surgery
Emerging library and tech:
- Dr Ashkan previously said the UK did the whole genome sequencing of 403 glioma tumors, but actually part of of the Genomics England's 100,000 Genomes Project that sequenced 100,000 genomes from "rare conditions or cancer"
- June 2023 Marnix Bosch talked about proteomics on the tumor lysate, "found... 25,000 MHC class 1 associated peptides... almost 13,000 class 2 associated peptides... 400 different tumor-associated peptides... all presented on the dendritic cells... to the immune system"
- Use liquid biopsy (blood draws) to obtain fragments of DNA shed by tumor cells, get biomarkers
What if the NWBO Franchise includes this:
- allogeneic vaccines made from tumor cells of donors (not patients), mass production and storage for off-the-shelf
- that becomes a library or a menu of vaccine components
- for which oncologists or Franchisee members can select antigens
- would then be loaded onto partially matured DCs from a patient’s apheresis
- would create a semi-personalized DCVax-L vaccine
- that is injected into the cancer patient
- and this version still retains all the benefits of the original DCVax-L (ie efficacy, non-toxic, immune memory)
- but this time more quickly, scalable, low cost, and without surgery
Bullish
Market Data 
Markets 
